Cooperative Agreement UG3CA290375
- Federal Grant Award Summary The National Cancer Institute awarded the University of Hawaii at Manoa a $402,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) for research investigating neutrophilic myeloid-derived suppressor cells (PMN-MDSCs) as an immunotherapy target in hepatoblastoma. The grant, effective from May 15, 2025 through April 30, 2027, will deliver preclinical research combining innovative mouse genetic approaches with therapeutic studies to determine how...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $426,425 to Baylor College of Medicine to conduct a pilot study examining the relationship between gut microbiome composition, metabolic dysfunction-associated steatotic liver disease (MASLD), and hepatocellular carcinoma (HCC). The key objectives of this 2-year study are to: 1) characterize baseline gut microbiome diversity associated with MASLD with and without HCC, 2)...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $2.88 million Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective August 5, 2025, through July 31, 2029. This award supports the development of etiology-adjusted precision liver cancer risk prediction tools and resources. The project focuses on developing non-invasive biomarkers and risk assessment strategies...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded Loyola University of Chicago a $461,844 project grant titled "Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver". The objective is to use novel hyperpolarized 13C probes to image glycolysis, a critical pathway in hepatocellular carcinoma (HCC) development, and establish in vivo imaging biomarkers to assess altered liver metabolism during HCC progression. The project aims to synthesize a...
- Imcare Biotech, Inc. received a $364,763 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded June 20, 2025, with a completion date of May 31, 2026. The grant funds development and validation of SerAvue AI, a novel multi-analyte algorithmic assay diagnostic designed for early detection of hepatocellular carcinoma (HCC). The diagnostic combines Imcare Biotech's proprietary LC-SPIK biomarker with established markers...
- Federal Project Grant Award Summary The University of Pittsburgh received a $261,662 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded December 1, 2025, with completion targeted for April 16, 2029. This award supports an integrated in silico and in vivo genetic screening research initiative designed to identify subtype-specific hepatocellular carcinoma (HCC) genetic dependencies. The project addresses a significant clinical...
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $5.03M project grant from the National Cancer Institute under the Cancer Centers Support Grants program (CFDA 93.397), awarded September 5, 2025, with completion scheduled for August 31, 2030. The UT Southwestern Liver Cancer Specialized Program of Research Excellence (SPORE) assembles a multidisciplinary team of basic, clinical, and translational scientists to develop personalized medical interventions...
- Federal Project Grant Award Summary Baylor College of Medicine received a $483,077 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2025 through May 31, 2030. The award supports fundamental research investigating three-dimensional circadian enhancer-promoter interactions mediated by estrogen-related receptor gamma (ESRRG) in the progression from nonalcoholic fatty liver disease (NAFLD) to hepatocellular carcinoma (HCC)....
- Federal Grant Award Summary Riboscience LLC received a $306,739 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded September 12, 2025, with completion targeted for August 31, 2026. The funding supports the development and evaluation of ENPP1 (ectonucleotide pyrophosphatase-phosphodiesterase 1) inhibitors for treating hepatocellular carcinoma (HCC), a particularly aggressive form of liver cancer with limited current therapeutic...
- This $396,061 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to assess the efficacy of a novel class of hypoxia-inducible factor (HIF) inhibitors as a potential treatment for renal cell carcinoma (RCC). The principal investigator has developed boron-based HIF inhibitors derived from the natural compound honokiol, which have demonstrated promising anti-angiogenic properties in vitro. This 2-year project aims to (1) determine...
DISCOVERY OF NOVEL NATURAL TEAD INHIBITORS FOR THE CHEMOPREVENTION OF LIVER TUMORS - PROJECT SUMMARY/ABSTRACT HEPATOCELLULAR CARCINOMA (HCC), THE MOST COMMON TYPE OF PRIMARY LIVER CANCER, IS A DIFFICULT DISEASE TO TREAT AND A LEADING CAUSE OF CANCER DEATHS WORLDWIDE WITH INCREASED INCIDENT RATE IN THE US. HCC HAS WELL CHARACTERIZED RISK FACTORS: CHRONIC HEPATITIS B VIRUS (HBV) OR HEPATITIS C VIRUS (HCV) INFECTION, LIVER CIRRHOSIS AND NON-ALCOHOLIC STEATOHEPATITIS (NASH), WHICH ACCOUNT FOR OVER 85% OF ALL HCC CASES. SUCH WELL-DEFINED POPULATION MAKES HCC AN IDEAL TYPE OF MALIGNANCY FOR CHEMOPREVENTION. HOWEVER, CURRENTLY THERE IS NO PREVENTION-INTERCEPTION DRUGS AVAILABLE FOR HCC. HENCE, THERE IS AN IMMINENT NEED TO DEVELOP EFFECTIVE AGENTS TO PREVENT AND INTERCEPT LIVER CANCER. HIPPO PATHWAY AND ITS TRANSCRIPTIONAL REGULATORS TEA DOMAIN TRANSCRIPTION FACTORS (TEAD) AND YAP/TAZ COMPLEXES HAVE BEEN SHOWN TO PLAY IMPORTANT ROLES IN TUMORIGENESIS. STUDIES FROM OUR AND OTHER LABS HAVE DEMONSTRATED THE KEY ROLES OF HIPPO PATHWAY IN HCC PATHOGENESIS. THEREFORE, TARGETING TEAD-YAP/TAZ COMPLEX COULD BE AN EFFECTIVE STRATEGY FOR HCC PREVENTION. OUR LONG-TERM GOAL IS TO IDENTIFY NOVEL HCC-PREVENTIVE NATURAL PRODUCTS (NPS) FROM UNDER- EXPLORED HAWAIIAN MICROORGANISMS AND OTHER NATURAL SOURCES. THE OBJECTIVE OF THIS PROPOSED RESEARCH IS TO DISCOVER NPS THAT INHIBIT TEAD PALMITOYLATION FOR THE PREVENTION AND INTERCEPTION OF HCC. THE CENTRAL HYPOTHESIS IS THAT THE UNDER-EXPLORED HAWAIIAN MICROORGANISMS AND NCI-NPS ARE EXCELLENT SOURCES FOR NEW CANCER PREVENTIVE NP DISCOVERY INCLUDING TEAD-P INHIBITORS. THE RATIONALE OF THE PROPOSED RESEARCH IS THAT ONCE NOVEL POTENT TEAD PALMITOYLATION INHIBITORS ARE IDENTIFIED, LEAD COMPOUNDS WILL BE STUDIED FOR THEIR MECHANISMS OF ACTION AND TESTED IN VIVO IN THE FOLLOW-UP STUDIES. THE OBJECTIVES OF THIS PROJECT WILL BE ACCOMPLISHED BY TWO SPECIFIC AIMS: (1) IDENTIFY HCC RELEVANT TEAD ISOFORM(S), IMPLEMENT BIOASSAY DEVELOPMENT, AND PERFORM A PILOT NP SCREENING; (II) PERFORM HTS, BGS, AND STRUCTURE DETERMINATION OF ACTIVE COMPOUNDS IN VITRO AND IN VIVO. THE PROPOSED PROJECT IS SIGNIFICANT AND HIGHLY TRANSLATIONAL BECAUSE THIS MULTI-PI GRANT AIMS AT IDENTIFYING NOVEL NPS WHICH INHIBIT TEAD PALMITOYLATION FOR HCC PREVENTION AND INTERCEPTION. THE RESULTS WILL LIKELY LEAD TO NEW CHEMOPREVENTION TRIALS TO INVESTIGATE THESE NEW NPS IN HIGH-RISK HCC POPULATION. THIS WOULD HAVE A PROFOUND EFFECT TO REDUCE THE BURDEN OF HCC ALL OVER THE WORLD.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $32.3k | 6/17/25 | ||
| Not listed | $290.6k | 4/23/25 | ||
| Not listed | $290.6k | 4/23/25 | ||
| Not listed | $334.3k | 5/14/24 | ||
| Not listed | $334.3k | 5/14/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
MA2122S | The General Hospital Corporation | Cooperative Agreement UG3CA290375 | $106.4k | 4/16/26 | |
MA2122S | The General Hospital Corporation | Cooperative Agreement UG3CA290375 | $106.3k | 7/3/25 |